ClinicalTrials.gg
Active, not recruitingNCT07709494Updated Oct 14, 2026

A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa

A Phase 1 interventional study of Rev-56 for Inhalation and Placebo: Normal saline in Healthy Participants and Non-cystic Fibrosis Bronchiectasis, sponsored by Revagenix, Inc.. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-14.

Sponsored by Revagenix, Inc. · Phase 1, Interventional, and Treatment

How we know

Updated Oct 14, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 65 studies in Bronchiectasis with a site in United States — 21 open to participants now, 23 under way, 2 of them phase 3. Bronchiectasis · United States.

Planned enrollment
28th of 52
64 · median 78
Started
2026
with 5 others
Phase 1
3 of 65
none open now
Primary completion
2027-07
later than 12 of 21 live
Registered
63rd of 65
by date

Among the 65 studies in Bronchiectasis with a site in United States, this one is the 28th largest by planned enrollment of the 52 interventional ones that give a count, is one of 6 that started in 2026, is one of 3 in phase 1, reaches primary completion later than 12 of the 21 other live ones, and was the 63rd registered.

Bronchiectasis

405 studies on the registry are indexed under Bronchiectasis; 126 are open to participants now.

Browse Bronchiectasis studies →

Open to participants now

21 of the 65 studies in Bronchiectasis with a site in United States are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 94 Bronchiectasis studies recruiting now, 51 (54%) set no upper age limit and 13 (14%) stop at 75 or younger; 13 take children under 18; 27 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies in Bronchiectasis with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 1a/1b study to test the safety, tolerability, microbiological response, and pharmacokinetics of inhaled Rev-56 compared to placebo in adult healthy participants and non-cystic fibrosis bronchiectasis (NCFB) patients with P. aeruginosa, respectively.

Phase 1a (Part A) will evaluate single doses of inhaled Rev-56 in adult healthy participants and includes up to 5 cohorts. Eligible participants will be randomized to active treatment or placebo in a 3:1 randomization scheme.

Phase 1b (Part B) will evaluate the safety, tolerability, microbiological response, and pharmacokinetics of multiple doses of inhaled Rev-56 in NCFB patients with P. aeruginosa and includes 2 cohorts evaluating once daily dosing and twice daily dosing, respectively. Eligible participants will be randomized to active treatment or placebo in a 2:1 randomization scheme.

03

Conditions studied

  • Healthy Participants
  • Non-cystic Fibrosis Bronchiectasis

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male and female participants aged 18 to 55 years, inclusive
  • > 18 to ≤ 32 kg/m\^2
  • (FEV1) ≥ 80%
  • ≥ 90 mL/min
  • Normal laboratory values and physical exam at screening, or Grade 1 abnormalities that are not

Inclusion Criteria (NCFB Patients with P. aeruginosa):

  • Male and female NCFB patients aged 18 to 80 years, inclusive
  • Bronchiectasis confirmed by prior computerized tomography (CT) scan
  • Chronic P. aeruginosa infection (≥ 2 positive cultures within prior 12 months)
  • Screening sputum culture positive for P. aeruginosa at ≥ 10\^4 CFU/mL
  • FEV1 ≥ 50% (post bronchodilator)

Exclusion criteria

Exclusion Criteria (Healthy Participants):

  • medical history
  • Acute illness within 4 weeks of screening
  • Current smoker or nicotine user
  • History of alcohol abuse (within prior 12 months) or drug/chemical abuse

Exclusion Criteria (NCFB Patients with P. aeruginosa):

  • Primary asthma, (COPD), or cystic fibrosis (CF)
  • More than 2 pulmonary exacerbations requiring IV antibiotics within 12 months prior to screening
  • Receipt of antibiotics (excluding macrolides) within 30 days prior to screening
  • Clinically significant hemoptysis requiring intervention within 30 days prior to screening
  • Receiving anti-infective treatment for concurrent nontuberculosis mycobacteria (NTM) or fungal infection
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Cohort 1a

    3.5 mg Rev-56 or placebo single dose

    Combination Product: Rev-56 for Inhalation · Drug: Placebo: Normal saline

  • Experimental
    Cohort 2a

    7 mg Rev-56 or placebo single dose

    Combination Product: Rev-56 for Inhalation · Drug: Placebo: Normal saline

  • Experimental
    Cohort 3a

    14 mg Rev-56 or placebo single dose

    Combination Product: Rev-56 for Inhalation · Drug: Placebo: Normal saline

  • Experimental
    Cohort 4a

    28 mg Rev-56 or placebo single dose

    Combination Product: Rev-56 for Inhalation · Drug: Placebo: Normal saline

  • Experimental
    Optional Cohort 5a

    ≤56 mg Rev-56 or placebo single dose

    Combination Product: Rev-56 for Inhalation · Drug: Placebo: Normal saline

  • Experimental
    Cohort 1b

    ≤28 mg Rev-56 or placebo once daily for 7 days

    Combination Product: Rev-56 for Inhalation · Drug: Placebo: Normal saline

  • Experimental
    Cohort 2b

    ≤28 mg Rev-56 or placebo twice daily for 7 days

    Combination Product: Rev-56 for Inhalation · Drug: Placebo: Normal saline

Interventions

  • Combination productRev-56 for Inhalation

    administered by inhalation via an investigational nebulizer device

  • DrugPlacebo: Normal saline

    administered by inhalation via an investigational nebulizer device

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment-emergent adverse events (AEs)

    Time frame: 21 days (healthy participants) or 28 days (NCFB patients with P. aeruginosa)

  2. Number of participants with clinically significant abnormalities in lab parameters, vital signs, respiratory function, and ECG parameters graded by FDA Toxicity Grading Scale (for healthy participants) and DAIDS Toxicity Tables (for NCFB patients)

    Time frame: 21 days (healthy participants) or 28 days (NCFB patients with P. aeruginosa)

Secondary outcomes

  1. Maximum observed concentration (Cmax) of Rev-56

    Time frame: Healthy Participants: predose, and 5 min, 15 min, 45 min, 90 min, 3h, 6h, 12h, 24h and 48h post inhalation; NCFB Patients: pre-dose, and 5 min, 15 min, 45 min, 90 min, 3h, 8h, 12h (Cohort 2b only) and 24h (Cohort 1b only) after completion of inhalation

  2. Time to Cmax of Rev-56 (Tmax)

    Time frame: Healthy Participants: predose, and 5 min, 15 min, 45 min, 90 min, 3h, 6h, 12h, 24h and 48h post inhalation; NCFB Patients: pre-dose, and 5 min, 15 min, 45 min, 90 min, 3h, 8h, 12h (Cohort 2b only) and 24h (Cohort 1b only) after completion of inhalation

  3. Area under the curve from time 0 to last measurable concentration (AUC0-last)

    Time frame: Healthy Participants: predose, and 5 min, 15 min, 45 min, 90 min, 3h, 6h, 12h, 24h and 48h post inhalation; NCFB Patients: pre-dose, and 5 min, 15 min, 45 min, 90 min, 3h, 8h, 12h (Cohort 2b only) and 24h (Cohort 1b only) after completion of inhalation

  4. Area under the curve from time 0 to 24 hours after completion of dosing (AUC0-24)

    Time frame: Healthy Participants: predose, and 5 min, 15 min, 45 min, 90 min, 3h, 6h, 12h, 24h and 48h post inhalation; NCFB Patients: pre-dose, and 5 min, 15 min, 45 min, 90 min, 3h, 8h, 12h (Cohort 2b only) and 24h (Cohort 1b only) after completion of inhalation

  5. Area under the curve from time 0 to infinity (AUC0-inf)

    Time frame: Healthy Participants: predose, and 5 min, 15 min, 45 min, 90 min, 3h, 6h, 12h, 24h and 48h post inhalation; NCFB Patients: pre-dose, and 5 min, 15 min, 45 min, 90 min, 3h, 8h, 12h (Cohort 2b only) and 24h (Cohort 1b only) after completion of inhalation

  6. Clearance of Rev-56 (CL/F)

    Time frame: Healthy Participants: predose, and 5 min, 15 min, 45 min, 90 min, 3h, 6h, 12h, 24h and 48h post inhalation; NCFB Patients: pre-dose, and 5 min, 15 min, 45 min, 90 min, 3h, 8h, 12h (Cohort 2b only) and 24h (Cohort 1b only) after completion of inhalation

  7. Half-life of Rev-56 (t½)

    Time frame: Healthy Participants: predose, and 5 min, 15 min, 45 min, 90 min, 3h, 6h, 12h, 24h and 48h post inhalation; NCFB Patients: pre-dose, and 5 min, 15 min, 45 min, 90 min, 3h, 8h, 12h (Cohort 2b only) and 24h (Cohort 1b only) after completion of inhalation

  8. Volume of distribution of Rev-56 (Vz/F)

    Time frame: Healthy Participants: predose, and 5 min, 15 min, 45 min, 90 min, 3h, 6h, 12h, 24h and 48h post inhalation; NCFB Patients: pre-dose, and 5 min, 15 min, 45 min, 90 min, 3h, 8h, 12h (Cohort 2b only) and 24h (Cohort 1b only) after completion of inhalation

  9. Minimum observed concentration of Rev-56 (Cmin)

    Time frame: NCFB Patients: pre-dose, and 5 min, 15 min, 45 min, 90 min, 3h, 8h, 12h (Cohort 2b only) and 24h (Cohort 1b only) after completion of inhalation

  10. Mean P. aeruginosa burden (CFU/mL) in sputum culture compared to baseline

    Time frame: 28 days (NCFB patients with P. aeruginosa)

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2026 (actual). Primary completion is estimated for Jul 2027, 12 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 14, 2026: primary completion Jun 2027 → Jul 2027 and completion Jun 2027 → Jul 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 2, 2026
First posted
Jul 16, 2026
StartActual
Jul 13, 2026
Primary completionEst.
Jul 2027was Jun 2027
CompletionEst.
Jul 2027was Jun 2027
Last update
Oct 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 14, 2026
Primary completion
Jun 2027→Jul 2027
Oct 14, 2026
Study completion
Jun 2027→Jul 2027
Oct 14, 2026
Show all 1 update
  1. Oct 14, 2026
    Recruiting→Active, not recruiting
    Primary completion Jun 2027→Jul 2027
    Study completion Jun 2027→Jul 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07709494
Lead sponsor
Revagenix, Inc.
Responsible party
Sponsor
First posted
Jul 16, 2026
Start date
Jul 13, 2026
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Oct 14, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion